NCT04231331View on ClinicalTrials.gov

Ertugliflozin for Functional Mitral Regurgitation

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions
Mitral Valve InsufficiencyLeft Ventricular Systolic Dysfunction
Interventions
DRUG

Ertugliflozin

Ertugliflozin 5mg qd for 12 months

DRUG

Placebo

Placebo qd for 12 months

Trial Locations (3)

Unknown

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Asan Medical Center

OTHER

NCT04231331 - Ertugliflozin for Functional Mitral Regurgitation | Biotech Hunter | Biotech Hunter